Real estate services firm in key appointment at £35m European hub scheme

Proposed QIAGEN reception area

QIAGEN, which operates in sample to insight solutions for molecular testing, has appointed Cushman & Wakefield to provide project and development services for its £35m new base in Manchester.

The firm will be acting as project managers, cost consultants, mechanical and electrical consultants and health and safety advisor to deliver the Cat A and B fit-out for QIAGEN’s European hub for diagnostics development, part of the Citylabs 2.0 development in Manchester.

QIAGEN has pre-let 92,000 sq ft, including life science laboratories and 40,000 sq ft of support office space, at the scheme which is due for completion in Spring 2021.

Its relocation from its current base at Manchester Science Park will see it become the anchor industrial partner in the genomics campus.

Citylabs 2.0 is the first phase of a £60m extension of the genomics campus for Manchester Science Partnerships (MSP) in a joint venture with Manchester University NHS Foundation Trust (MFT).

It is located within Europe’s largest clinical academic campus and is surrounded by the Manchester Royal Infirmary, Royal Manchester Children’s Hospital, Saint Mary’s Hospital and Manchester Royal Eye Hospital.

Gareth Collins-Jones, head of Northern project management at Cushman & Wakefield, said: “We are delighted to have been commissioned to provide full construction-related services to our globally-renowned client QIAGEN on this major European hub for research and development in life science.

“Our focus is to deliver a highly technical and exceptional workplace on time and within our client’s budget and work with the many outside stakeholders of the development, including NHS and Manchester Science Park.

“We will complete this significant project in Spring 2021 and enable a smooth transitional phased move from the current research facility whilst maintaining ongoing research projects.”

QIAGEN is a global provider of sample to insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life.

It provides solutions to more than 500,000 customers around the world in molecular diagnostics (human healthcare) and life sciences (academia, pharma R&D and industrial applications, primarily forensics).

As of June 30, 2020, QIAGEN employed approximately 5,200 people in more than 35 locations worldwide.

The company currently has about 270 employees in Manchester and is committed to further growth.